Gemeinsame Stellungnahme der DGHO, AIO, DEGRO und DGVS zur Nutzenbewertung von Nivolumab (Plattenepithelkarzinom des Ösophagus, nach Vorbehandlung)

• Literatur

• 1 S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Dezember 2018 https://www.awmf.org/leitlinien/detail/ll/021-023OL.html
• 2 Stahl M. et al Ösophaguskarzinom, Onkopedia. Dezember 2018 https://www.onkope-dia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 3 Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut. Krebs in Deutschland 2015–2016, Häufigkeiten und Trends: Ösophagus. 2020 12. Ausgabe. 28-30
• 4 Moehler M, Maderer A, Thuss-Patience PC. et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol 2020; 31: 228-235
• 5 Lagergren J, Smyth E, Cunningham D. et al. Oesophageal cancer. Lancet 2017; 390: 2383-2396
• 6 Conroy T, Galais M-P, Raoul J-L. et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5 / ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014; 15: 305-314
• 7 Adenis A, Bennouna J, Etienne P. et al Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). Eur J Cancer 2019; 111: 12-20 . DOI: Thallinger CMR, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 10. Dezember 29:4709–4714, 2011. DOI:10.1200/JCO.2011.36.7599
• 8 Abraham P, Gricar J, Zhang Y. et al. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma. Adv Ther 2020; 37: 3392-3403
• 9 Kato K, Cho B, Takahashi M. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol 2019; 20: 1506-1517
• 10 Kojima T, Shah MA, Muro K. et al. Randomized Phase III KEYNOTE-181 Study of Pembroli- zumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020; 38: 4138-4148
• 11 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 12 Cherny NI, Dafni U, Bogaerts J. et al. ESMO-Magnitude of Clinical Benefit Scale version1.1. Ann Oncol 2017; 28: 2340-2366